Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.

INTRODUCTION Angiogenesis and inflammation are both important to the pathogenesis of malignancies. Androgen deprivation therapy (ADT) for prostate cancer causes drastic hormonal changes that alter both disease and host factors. We measured inflammatory and angiogenic biomarkers in ADT-treated and control groups of men with prostate cancer. MATERIALS AND METHODS Baseline and 12-week plasma samples were collected from 37 ADT-naïve men with locally advanced or recurrent prostate cancer. Of those, 23 initiated ADT with a gonadotropin-releasing hormone (GnRH) agonist and 14 served as nontreatment controls. Samples were tested for a panel of angiogenic and inflammatory biomarkers. RESULTS The treatment group had significantly higher concentrations of the inflammatory biomarkers interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor (TNF)-α, and stromal cell-derived factor (SDF)-1α. None of the angiogenic biomarkers were significantly different between the groups at baseline. Among patients with a short prostate-specific antigen (PSA) doubling time (<6 months), the proangiogenic factor basic fibroblast growth factor (bFGF) was lower at baseline. In the treatment group, plasma placental growth factor (PlGF) increased and IL-6 decreased after 12 weeks of ADT. Moreover, the treatment group continued to have significantly higher concentrations of the inflammatory biomarkers IL-1β, IL-8, and SDF-1α as well as bFGF than controls. DISCUSSION These men were characterized by elevations in several traditional markers of aggressive disease and also by higher levels of several inflammatory biomarkers. Although ADT decreased IL-6 levels, IL-1β, IL-8, and SDF-1α remained significantly higher than in controls. The role of these biomarkers should be further explored.

[1]  F. Callera,et al.  Three-dimensional conformal radiotherapy in prostate cancer patients: rise in interleukin 6 (IL-6) but not IL-2, IL-4, IL-5, tumor necrosis factor-α, MIP-1-α, and LIF levels. , 2012, International journal of radiation oncology, biology, physics.

[2]  E. Antonarakis,et al.  The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation , 2011, The Prostate.

[3]  D. Collins,et al.  Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. , 2011, International journal of radiation oncology, biology, physics.

[4]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[5]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[6]  P. Kantoff,et al.  A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. M. Nagaraja,et al.  Radiation therapy induces circulating serum Hsp72 in patients with prostate cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  A. Zietman.  Evidence-based medicine, conscience-based medicine, and the management of low-risk prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Florence T. H. Wu,et al.  A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use , 2009, Journal of cellular and molecular medicine.

[10]  Cynthia Ménard,et al.  Longitudinal Cytokine Expression during IMRT for Prostate Cancer and Acute Treatment Toxicity , 2009, Clinical Cancer Research.

[11]  Tung‐Kwang Lee,et al.  Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression. , 2009, In vivo.

[12]  Christian Fischer,et al.  FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? , 2008, Nature Reviews Cancer.

[13]  D. Nathan,et al.  Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. , 2008, Urology.

[14]  C. Ménard,et al.  Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. , 2007, Cancer research.

[15]  E. Metter,et al.  Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. , 2006, Journal of andrology.

[16]  P. Kantoff,et al.  Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. , 2006, Clinics.

[17]  F. Rojo,et al.  Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. , 2006, Histology and histopathology.

[18]  P. Dell’Era,et al.  Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. , 2005, Cytokine & growth factor reviews.

[19]  P. Kantoff,et al.  The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480 , 2005, Clinical Cancer Research.

[20]  K. Channer,et al.  The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. , 2004, The Journal of clinical endocrinology and metabolism.

[21]  D. Hicklin,et al.  A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. , 2004, Molecular cancer research : MCR.

[22]  M. Oshimura,et al.  Soluble c-kit receptor mobilizes hematopoietic stem cells to peripheral blood in mice. , 2004, Experimental hematology.

[23]  J. Karam,et al.  Prostate-specific antigen doubling time predicts response to deferred antiandrogen therapy in men with androgen-independent prostate cancer. , 2003, Urology.

[24]  M. Evans,et al.  Cytokine profiles in patients receiving wide-field + prostate boost radiotherapy (xRT) for adenocarcinoma of the prostate. , 2003, Cytokine.

[25]  Kazuto Ito,et al.  Placental growth factor gene expression in human prostate cancer and benign prostate hyperplasia. , 2003, Anticancer research.

[26]  P. Heinrich,et al.  Principles of interleukin (IL)-6-type cytokine signalling and its regulation. , 2003, The Biochemical journal.

[27]  B. Gigante,et al.  Structure and function of placental growth factor. , 2002, Trends in cardiovascular medicine.

[28]  W. O'Fallon,et al.  Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. , 2002, The Journal of clinical endocrinology and metabolism.

[29]  P. Kantoff,et al.  Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  V. Broudy,et al.  Soluble Kit receptor blocks stem cell factor bioactivity in vitro. , 2001, Leukemia research.

[31]  P. Kantoff,et al.  Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. , 2001, Cancer research.

[32]  R. Montironi,et al.  Vascular endothelial growth factor expression and capillary architecture in high‐grade PIN and prostate cancer in untreated and androgen‐ablated patients , 2000, The Prostate.

[33]  G. Wise,et al.  Cytokine variations in patients with hormone treated prostate cancer. , 2000, The Journal of urology.

[34]  A. Whitehead,et al.  Serum amyloid A, the major vertebrate acute-phase reactant. , 1999, European journal of biochemistry.

[35]  P. Kantoff,et al.  Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. , 1999, Urology.

[36]  A. Whitehead,et al.  Regulation of serum amyloid A protein expression during the acute-phase response. , 1998, The Biochemical journal.

[37]  R K Jain,et al.  Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  K. Plate,et al.  Vascular endothelial growth factor , 1997, Journal of Neuro-Oncology.

[39]  V. Laudone,et al.  Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. , 1997, The Journal of urology.

[40]  H. Atkins,et al.  Identification and characterization of a soluble c-kit receptor produced by human hematopoietic cell lines. , 1995, Blood.

[41]  T. Springer.  Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm , 1994, Cell.

[42]  S. Bandinelli,et al.  Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. , 2006, The Journal of clinical endocrinology and metabolism.

[43]  V. Laudone,et al.  Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. , 1998, Urology.

[44]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.